市場調查報告書

腦瘤治療的全球市場 - 成長,趨勢,預測(2019年∼2024年)

Brain Tumor Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 391488
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
Back to Top
腦瘤治療的全球市場 - 成長,趨勢,預測(2019年∼2024年) Brain Tumor Therapeutics Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年05月01日內容資訊: 英文 114 Pages
簡介

美國的2016年的腦瘤全國總計調查,推測2017年美國有2萬6070件原發性惡性腫瘤,並且報告有5萬3,200件新的非惡性腫瘤。全世界的腦瘤盛行率的上升促進腦瘤治療市場成長。

本報告提供全球腦瘤治療市場調查,市場概要,各種類、治療方法、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 腦瘤的發生率上升
    • 主要企業的強力研究開發舉措
    • 癌症啟發的政府配合措施增加
  • 市場阻礙因素
    • 癌症治療的成本高
  • 波特的五力分析
    • 買方議價能力
    • 供給企業談判力
    • 新加入業者的威脅
    • 替代品的威脅
    • 競爭企業間的敵對關係

第5章 市場區隔

  • 各類型
    • 神經膠質母細胞瘤
    • 腦膜瘤
    • 下垂體腫瘤
    • 其他
  • 各治療
    • 人組織工程
    • 免疫療法
    • 基因治療
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Amgen Inc.
    • AstraZeneca PLC
    • Bayer AG
    • Bristol-Myers Squibb Co
    • Eisai
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline PLC
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.

第7章 市場機會及未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 54538

Market Overview

A brain tumor occurs when abnormal cells from within the brain. There are two major types of tumors, malignant or cancerous tumors and benign tumors. Increasing incidence of the brain tumor is one of the major factors which is driving the growth of the market globally. As per the Central Brain Tumor Registry of the United States report 2016, an estimated 79,270 new cases of primary malignant, nonmalignant are anticipated to be diagnosed in the US in 2017 (26,070 primary malignant and 53,200 nonmalignant). The rising prevalence of brain cancer cases across the globe is expected to drive the demand of the brain tumor therapeutics market over the forecast period. The high cost of cancer therapy is one of the major factors restraining the growth of the market studied. The treatment for brain tumor differs depending on several factors, such as age, general health, and the size, location, and type of tumor. Furthermore, there are some adverse effects of the treatments that are restraining the growth of the market studied, over the forecast period.

Scope of the Report

Brain tumor arises from abnormal growth of cancerous cells in the brain. A brain tumor is one of the leading causes of death, globally. Meningioma is the most common kind of brain tumor and the hardest to treat, while, treatments for glioma usually have better outcomes.

Key Market Trends

Immunotherapy Segment is Expected to Register Robust Growth

Immunotherapy is the treatment of disease by activating or suppressing the immune system. Vaccines are a promising new form of immunotherapy that stimulates the immune system to fight cancer. The use of immunotherapy in glioblastoma multiforme which is the most common primary malignant brain tumor in adults has been found to be effective. In 2018, a European trial succeeded in proving the feasibility and efficacy of treating brain cancer with personalized immunotherapy tailored for each patient. This phase I/II trial that runs across six European centers, tested a combination of two personalized vaccines in patients with glioblastoma. These clinical trials are expected to drive the market studied.

The United States is Expected to Retain Largest Market Share During the Period of Forecast.

The US dominates the brain tumor treatment market in North America. The US is anticipated to lead the market owing to the developed healthcare industry coupled with rising awareness regarding advanced technologies amongst the population in this region. In the United States, the incidence of all primary malignant and non-malignant brain and other CNS tumors is 22.36 cases per 100,000, for a total count of 368,117 tumor incidences. Meningioma is the most common form of brain tumor, followed by Gliomas. Eflornithine is designated as an orphan drug in the United States and received Breakthrough Therapy Designation in the country for the treatment of anaplastic Glioma

Competitive Landscape

The market for brain tumor therapeutics is highly concentrated with a few global players controlling a significant share of the market. Key players in the market include Amgen Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Co, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co. Inc., Novartis AG, and Pfizer Inc. among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Brain Tumor
    • 4.2.2 Strong R&D Initiatives from Key Players
    • 4.2.3 Increasing Government Initiatives for Cancer Awareness
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Cancer Therapies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Type of Brain Cancer
    • 5.1.1 Glioblastoma
    • 5.1.2 Meningioma
    • 5.1.3 Pituitary Tumors
    • 5.1.4 Other Types of Brain Cancer
  • 5.2 By Therapy
    • 5.2.1 Tissue Engineering
    • 5.2.2 Immunotherapy
    • 5.2.3 Gene Therapy
    • 5.2.4 Other Therapies
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc.
    • 6.1.2 AstraZeneca PLC
    • 6.1.3 Bayer AG
    • 6.1.4 Bristol-Myers Squibb Co
    • 6.1.5 Eisai Inc.
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 GlaxoSmithKline PLC
    • 6.1.8 Johnson & Johnson
    • 6.1.9 Merck & Co. Inc.
    • 6.1.10 Novartis AG
    • 6.1.11 Pfizer Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top